Adaptive Biotechnologies Corporation (NASDAQ:ADPT) went up by 12.26% from its latest closing price compared to the recent 1-year high of $43.40. The company’s stock price has collected 21.68% of gains in the last five trading sessions. Barron’s reported on 03/08/21 that FDA Authorizes New Category of Covid-19 Test
Is It Worth Investing in Adaptive Biotechnologies Corporation (NASDAQ :ADPT) Right Now?
Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Adaptive Biotechnologies Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $16.25, which is $6.6 above the current price. ADPT currently public float of 139.85M and currently shorts hold a 4.54% ratio of that float. Today, the average trading volume of ADPT was 1.57M shares.
ADPT’s Market Performance
ADPT stocks went up by 21.68% for the week, with a monthly jump of 10.13% and a quarterly performance of -34.19%, while its annual performance rate touched -78.76%. The volatility ratio for the week stands at 8.63% while the volatility levels for the past 30 days are set at 9.04% for Adaptive Biotechnologies Corporation. The simple moving average for the period of the last 20 days is 18.85% for ADPT stocks with a simple moving average of -57.56% for the last 200 days.
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with Piper Sandler repeating the rating for ADPT by listing it as a “Neutral.” The predicted price for ADPT in the upcoming period, according to Piper Sandler is $7.50 based on the research report published on June 03rd of the current year 2022.
JP Morgan, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $50, previously predicting the price at $75. The rating they have provided for ADPT stocks is “Overweight” according to the report published on February 16th, 2022.
Goldman gave a rating of “Neutral” to ADPT, setting the target price at $21 in the report published on February 16th of the current year.
ADPT Trading at 5.34% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.95% of loss for the given period.
Volatility was left at 9.04%, however, over the last 30 days, the volatility rate increased by 8.63%, as shares surge +16.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.80% lower at present.
During the last 5 trading sessions, ADPT rose by +21.68%, which changed the moving average for the period of 200-days by -78.13% in comparison to the 20-day moving average, which settled at $7.38. In addition, Adaptive Biotechnologies Corporation saw -69.00% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ADPT starting from ADAMS R MARK, who sale 831 shares at the price of $13.17 back on Apr 07. After this action, ADAMS R MARK now owns 122,893 shares of Adaptive Biotechnologies Corporation, valued at $10,944 using the latest closing price.
ROBINS CHAD M, the CEO and Chairman of Adaptive Biotechnologies Corporation, sale 14,815 shares at $12.46 during a trade that took place back on Mar 09, which means that ROBINS CHAD M is holding 1,916,154 shares at $184,595 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -135.39 for the present operating margin
- +59.02 for the gross margin
The net margin for Adaptive Biotechnologies Corporation stands at -134.30. Equity return is now at value -36.70, with -24.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.